Health TrialsbyHealthPanel

Investigating Neural Biomarkers for Gait in Parkinson's Patients

ConditionsParkinson DiseaseGait Disorders, Neurologic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSwiss Federal Institute of Technology

About this trial

This observational study's main goal is to learn more about the neural mechanisms during movement in Parkinson's disease. Furthermore, it aims to inspire personalised treatment options.

Participants will undergo a protocol that involves walking and gait-related motor tasks, such as seated stepping. During the protocol, brain activity will be recorded.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

must have given informed consent as documented by signature

agree to comply with the study procedures

no neurological, orthopedic, or rheumatologic disease history

no identified sensory impairment.

Disqualifiers

Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) < 20

History of physical or neurological condition that interferes with study procedures

Social and/or personal circumstances interfering with the ability to come to the session

Trial population

Participants will be recruited among students, employees and associated persons of ETH Zürich, the University of Zürich, the University Hospital of Zürich, and Balgrist University Hospital and other centers.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Neural Activity Recording

    Diagnostic test

    Neural Activity is measured using EEG in all groups. Additionally, in Parkinson's patients, local-field-potentials from deep brain stimulation electrodes are recorded.

  • Movement Parameter Recording

    Diagnostic test

    Gait-related movement parameters are non-invasively recorded using motion capture, accelerometers and electromyography.

  • Neuromodulation

    Other intervention

    Neural signals are recorded with the electrodes of the deep brain stimulation device. Parkinson's patients are asked to modulate their neural activity by observing the streamed neural activity and applying mental strategies.

Treatment groups

60 Participants
are divided into 3 treatment groups
Group A: Young, healthy control2 interventions
Group B: Age-matched healthy control2 interventions
Group C: Parkinson's patients3 interventions

Trial outcomes

Primary outcomes

1

Cortical activity underlying kinematic gait patterns will be recorded by electroencephalograph of the healthy and Parkinson patients

Using a mobile EEG system to measure neural activity during walking

Time frame
30 minutes
2

Electromyography (Delsys®) of the healthy and Parkinson patients

Electrodes will be attached to a representative lower limb muscle, such as the tibialis anterior.

Time frame
30 minutes
3

Detect onset of task-related movements detected by an accelerometer that will be placed on the hand and foot of the healthy and the parkinson patients

ZurichMOVE® detects onset of movements

Time frame
30 minutes

Secondary outcomes

1

Compare cortical activity between healthy subjects and parkinson patients

Neural activity between healthy controls and partient cohort will be compared.

Time frame
30 minutes

Other outcomes

1

Difference in movement frequency between healthy participants and PD patients

Analysing the difference between healthy subjects and PD patients

Time frame
15 minutes
2

Difference in the range of motion between healthy participants and PD patients

Analysing the difference between healthy subjects and PD patients

Time frame
15 minutes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Swiss Federal Institute of Technology

Lead sponsor

cereneo center for Neurology and Rehabilitation

Collaborator

University of Zurich

Collaborator

Source ClinicalTrials.gov
Apply now